Compare PII & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PII | LQDA |
|---|---|---|
| Founded | 1954 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 1994 | 2020 |
| Metric | PII | LQDA |
|---|---|---|
| Price | $54.03 | $34.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $57.50 | $38.60 |
| AVG Volume (30 Days) | 713.9K | ★ 1.7M |
| Earning Date | 04-27-2026 | 06-15-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,152,000,000.00 | $158,320,000.00 |
| Revenue This Year | $1.52 | $993.31 |
| Revenue Next Year | $4.29 | $219.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $30.92 | $11.26 |
| 52 Week High | $75.25 | $46.67 |
| Indicator | PII | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 27.11 | 45.29 |
| Support Level | $46.03 | $30.48 |
| Resistance Level | $60.88 | $36.07 |
| Average True Range (ATR) | 2.52 | 2.66 |
| MACD | -1.08 | -0.19 |
| Stochastic Oscillator | 3.41 | 42.07 |
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to pontoon and deck boat users. It is slated to divest its Indian motorcycle brand to Carolwood in the first quarter of 2026. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.